Related Experiment Video
Updated: Aug 3, 2026

A New Single Chamber Implantable Defibrillator with Atrial Sensing: A Practical Demonstration of Sensing and Ease of Implantation
Published on: February 28, 2012
The Defibrillator in Acute Myocardial Infarction Trial (DINAMIT): rationale, design and specific aims
Gerian Grönefeld1, Stuart J Connolly, Stefan H Hohnloser
1Department of Medicine, Division of Cardiology, J.W. Goethe-University, Frankfurt, Germany.
Insights
Implantable defibrillators (ICDs) reduce mortality in cardiac arrest survivors. This paper reviews ICDs for primary prevention, focusing on the Defibrillator in Myocardial infarction (DINAMIT) trial and early post-myocardial infarction patients.
Area of Science:
- Cardiology
- Electrophysiology
- Preventive Medicine
Background:
- Implantable defibrillators (ICDs) are proven to reduce mortality in patients post-cardiac arrest.
- Existing research on ICDs for primary prevention primarily involves coronary artery disease and non-ischemic cardiomyopathy.
- A gap exists in understanding ICD efficacy early after myocardial infarction.
Purpose of the Study:
- To review the rationale and design of the Defibrillator in Myocardial infarction (DINAMIT) trial.
- To compare the DINAMIT trial with other studies on primary prevention of sudden cardiac death.
- To highlight the role of ICDs in patients early after myocardial infarction.
Main Methods:
- Prospective randomized trials comparing ICDs with optimal medical therapy.
- Analysis of data from completed studies with patient enrollment and follow-up.
- Review of existing literature on ICDs for primary prevention in various cardiac conditions.
Main Results:
- The abstract anticipates new data from ongoing studies within 12 months.
- Previous trials have established ICD benefits in specific patient groups.
- The DINAMIT trial specifically addresses ICD use early post-myocardial infarction.
Conclusions:
- Further data is expected to clarify the role of ICDs in primary prevention.
- The DINAMIT trial is crucial for understanding ICD benefits in the early post-myocardial infarction phase.
- Optimal medical therapy remains a key comparison point for ICD efficacy.
Abstract:
The implantable defibrillator (ICD) effectively palliates arrhythmogenic events and thereby reduces total mortality in patients after a first episode of cardiac arrest. At present, four randomized controlled trials have addressed the issue of primary prevention by the ICD in patients with coronary artery disease and two small studies are available dealing with patients suffering from nonischemic cardiomyopathy. Importantly, none of the randomized studies in patients suffering from coronary artery disease has examined the potential role of the ICD in patients early after myocardial infarction. Within the next 12 months, important additional data is expected from several studies which have completed patient enrollment and follow-up. All studies are prospective randomized trials investigating the effects of ICD compared to optimal medical therapy. This paper summarizes the rationale, design and specific contributions of the Defibrillator in Myocardial infarction trial (DINAMIT) in comparison to other relevant studies on primary prevention of sudden cardiac death.
Related Concept Videos
Heart Failure Drugs: Inotropic Agents
Dysrhythmias VI: Management of Dysrhythmias
Cardiopulmonary Resuscitation III: AED Use
Cardiomyopathy II: Dilated Cardiomyopathy

